Aingle-angel oral etoposide in patients with relapsed or refractory extensive small-cell lung cancer

Objective: To evaluate the effectiveness and toxicity of prolonged low-dose oral etoposide in patients with relapsed or refrac-tory extensive small-cell lung cancer. Patients and Design: Thirty-one patients with relapsed or refractory extensive SCLC were treated with oral etoposide 50 mg (25 mg bid) for 14 days every 3 weeks. Response, duration of response, survival and toxicity were evaluated. Setting: Departments of Pulmonary Medicine and Medical Oncology, School of Medicine, Ege University. Complete response was not observed. Median duration of response was 16 weeks. Median survival was 16 weeks (range, 4-48 weeks). Two patients developed grade 3 leukopenia and 6 had grade 1-2 leukopenia. Two patients had grade 1-2 thrombocytopenia One patient developed grade 2 nausea/vomiting, and one patient grade 2 diarrhea. Conclusion: Prolonged administration of low-dose oral etoposide is well tolerated in relapsed or refractory SCLC and has thera-peutic efficacy.Objective: To evaluate the effectiveness and toxicity of prolonged low-dose oral etoposide in patients with relapsed or refrac-tory extensive small-cell lung cancer. Patients and Design: Thirty-one patients with relapsed or refractory extensive SCLC were treated with oral etoposide 50 mg (25 mg bid) for 14 days every 3 weeks. Response, duration of response, survival and toxicity were evaluated. Setting: Departments of Pulmonary Medicine and Medical Oncology, School of Medicine, Ege University. Complete response was not observed. Median duration of response was 16 weeks. Median survival was 16 weeks (range, 4-48 weeks). Two patients developed grade 3 leukopenia and 6 had grade 1-2 leukopenia. Two patients had grade 1-2 thrombocytopenia One patient developed grade 2 nausea/vomiting, and one patient grade 2 diarrhea. Conclusion: Prolonged administration of low-dose oral etoposide is well tolerated in relapsed or refractory SCLC and has thera-peutic efficacy